Precision BioSciences, Inc. filings document regulatory disclosures for a clinical-stage gene editing company built around the ARCUS platform and in vivo therapeutic candidates. Recent Forms 8-K furnish operating results, financial-condition updates, business presentations, and Regulation FD materials covering PBGENE-HBV in chronic hepatitis B and PBGENE-DMD in Duchenne muscular dystrophy, including IND-related and clinical-development disclosures.
The company’s proxy materials address board and stockholder meeting matters, executive compensation, equity plans, and governance proposals. Other filing categories cover material agreements, shareholder voting matters, capital-structure disclosures, inducement awards, and forward-looking risk language tied to clinical development, financing capacity, regulatory review, and public-company reporting.
Empery Asset Management, LP and Ryan M. Lane report beneficial ownership of 1,314,393 shares of Precision BioSciences, Inc. common stock, including 538,300 shares issuable upon exercise of warrants. This represents 4.99% of the common stock, based on 25,802,247 shares outstanding as of April 30, 2026.
The warrants contain a 4.99% beneficial ownership blocker, so the holders cannot exercise them to the extent their ownership would exceed 4.99% of the outstanding shares. Voting and dispositive power over these shares is shared, with no sole power reported. The filing confirms ownership of 5 percent or less of the class.
Precision BioSciences, Inc. restructured its senior leadership team, effective August 1, 2026. Alex Kelly, age 60, was promoted from Chief Financial Officer to Chief Operating Officer with an annual base salary of $510,000 and a target annual bonus equal to 45% of base salary.
The Board appointed Naresh Tanna, age 45, as Chief Financial Officer and principal financial officer with a base salary of $400,000 and a 40% target bonus, pro-rated for 2026. Vice President of Finance Mei Burris, age 40, will assume responsibilities as principal accounting officer and Chief Accounting Officer. A related press release states these leadership updates support advancement of the PBGENE-HBV and PBGENE-DMD in vivo gene editing programs toward upcoming clinical milestones.
Lynx1 Capital Management LP and Weston Nichols report beneficial ownership of shares of Precision BioSciences, Inc. common stock. Through Lynx1 Master Fund LP, they beneficially own 1,390,611 shares of common stock, with shared voting and dispositive power over all of these shares and no sole voting or dispositive power.
This position represents 5.4% of Precision BioSciences’ common stock, based on 25,802,247 shares outstanding as of April 30, 2026, as reported by the company. The Lynx1 Fund has the right to receive dividends and sale proceeds from the shares. The reporting persons state that their filing should not be construed as an admission of beneficial ownership for all purposes.
Precision BioSciences, Inc. furnished an updated corporate deck highlighting clinical progress in its gene-editing programs. In chronic hepatitis B, PBGENE-HBV from the ELIMINATE-B study showed liver biopsy data where it directly eliminated cccDNA, leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. The company is targeting year-end 2026 for the next update on this program.
The deck also notes activation of a second clinical site at Washington University School of Medicine in St. Louis for the FUNCTION-DMD trial evaluating PBGENE-DMD for Duchenne muscular dystrophy, with initial safety data also targeted for year-end 2026. The information is furnished under Regulation FD and not deemed filed for liability purposes.
Precision BioSciences, Inc. entered into a First Amendment to its Amended and Restated Loan and Security Agreement with Banc of California on June 10, 2026. This amendment extends the maturity date of the company’s Term Loan from June 30, 2027 to December 31, 2029, giving the company a longer period before the loan must be repaid under the existing facility.
Brown Melinda reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Melinda Brown received a grant of 20,979 restricted stock units (RSUs) tied to common stock. Each RSU represents a right to receive one share of common stock. The RSUs vest on the earlier of June 3, 2027, or the day before the company’s next annual stockholder meeting following the grant date, assuming she continues serving the company through that vesting date. After this grant, she holds 20,979 RSUs directly.
Frankel Stanley reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Stanley Frankel received a grant of 20,979 restricted stock units. Each RSU represents a contingent right to one share of common stock. The RSUs vest on the earlier of June 3, 2027 or the day before the next annual stockholder meeting, subject to his continued service.
Germano Geno J reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Geno J. Germano received a grant of 20,979 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the company’s common stock. The RSUs vest on the earlier of June 3, 2027 or the day immediately before the next annual stockholders’ meeting following the grant date, subject to his continued service with the company.
Pire Shari Lisa reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Shari Lisa Pire received a new equity grant. She was awarded 20,979 restricted stock units (RSUs), each representing a right to receive one share of the company’s common stock if vesting conditions are met.
The RSUs vest on the earlier of June 3, 2027 or the day immediately before the company’s next annual stockholder meeting following the grant date, provided she continues serving the company through that vesting date. After this grant, she holds 20,979 RSUs directly.
Buehler Kevin reported acquisition or exercise transactions in this Form 4 filing.
PRECISION BIOSCIENCES INC director Kevin Buehler received a grant of 20,979 Restricted Stock Units (RSUs), each representing a contingent right to one share of common stock. These RSUs vest on the earlier of June 3, 2027, or the day immediately before the company’s next annual stockholder meeting, subject to his continued service. Following this compensation-related award, Buehler holds 20,979 RSUs directly.